Follow us on:

Linkedin Facebook

Poolbeg Pharma notify that Schroders PLC increase holding to 5.13%

Share price

Poolbeg Pharma plc (LON:POLB) have today announced a TR-1: Notification of major interest in shares. The company published the note stating Schroders PLC now own 25,641,941.00 voting rights, its previous position was under the reportable threshold. This means that Schroders now hold an indirect interest of 5.128388% in Poolbeg Pharma. The transaction took place on the 18th May 2022.

Poolbeg Pharma plc (LON: POLB, OTCQB: POLBF), is a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model which enables them to develop multiple products faster and more cost effectively than the traditional biotech model.

Poolbeg aspires to become a “one-stop shop” for big pharma to find Phase II ready products for development and commercialisation.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Poolbeg Pharma

Poolbeg Pharma update on potential combination with HOOKIPA

Poolbeg Pharma and HOOKIPA Pharma propose a new collaboration with Gilead Sciences set to invest up to $8.7495 million, pending further negotiations.
Poolbeg Pharma

Poolbeg Pharma y HOOKIPA Pharma actualizan su recaudación de fondos con el apoyo de Gilead Sciences

Los Consejos de Poolbeg Pharma y HOOKIPA Pharma anuncian el respaldo de Gilead para una posible oferta y la actualización de su recaudación de fondos.
Poolbeg Pharma

Poolbeg Pharma and HOOKIPA Pharma fundraise update with Gilead Sciences’ support

Poolbeg Pharma and HOOKIPA Pharma confirm Gilead Sciences' support for participation in a $30 million+ private placement fundraise amid potential merger talks.
Poolbeg Pharma

HOOKIPA Pharma and Poolbeg discuss all-share acquisition

HOOKIPA Pharma and Poolbeg Pharma are exploring a potential all-share acquisition, aiming to create a powerful Nasdaq-listed biopharmaceutical entity.
Poolbeg Pharma

Poolbeg Pharma plc presents POLB 001 pre-clinical study data at the 66th ASH meeting

Poolbeg Pharma unveils promising POLB 001 data at ASH Meeting, highlighting its potential as a CRS preventative therapy in cancer immunotherapies.
Poolbeg Pharma

Poolbeg Pharma awarded POLB 001 patent in United States

Poolbeg Pharma secures US patent approval for POLB 001, enhancing its IP portfolio and advancing treatments for severe influenza and cytokine storms.

Latest interviews

View all interviews 

Company Presentations

View all Company Presentations

Brokers Talk

View all Broker Talk

FTSE 100 News

Search

Search

Green News

View all Sustainable sectors, Plcs and news  

Q&A's

View all Question and Answers

Funds

View all Funds, Market Insights and news

UK Broker Ratings

Hardman & Co

Don't Miss Our News Alerts

Subscribe Free

Find us on:

Linkedin Facebook

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2025 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.